CY1117879T1 - Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων - Google Patents

Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων

Info

Publication number
CY1117879T1
CY1117879T1 CY20161100786T CY161100786T CY1117879T1 CY 1117879 T1 CY1117879 T1 CY 1117879T1 CY 20161100786 T CY20161100786 T CY 20161100786T CY 161100786 T CY161100786 T CY 161100786T CY 1117879 T1 CY1117879 T1 CY 1117879T1
Authority
CY
Cyprus
Prior art keywords
water
salt
crystalline
acetone
carbon atoms
Prior art date
Application number
CY20161100786T
Other languages
Greek (el)
English (en)
Inventor
Claudio Giordano
Erwin Waldvogel
Original Assignee
Newron Pharmaceuticals S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharmaceuticals S.P.A. filed Critical Newron Pharmaceuticals S.P.A.
Publication of CY1117879T1 publication Critical patent/CY1117879T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/22Separation; Purification; Stabilisation; Use of additives
    • C07C231/24Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20161100786T 2010-04-27 2016-08-10 Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων CY1117879T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10161207 2010-04-27
PCT/EP2011/055309 WO2011134763A1 (en) 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
EP11714958.3A EP2563355B1 (en) 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers

Publications (1)

Publication Number Publication Date
CY1117879T1 true CY1117879T1 (el) 2017-05-17

Family

ID=42634917

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100786T CY1117879T1 (el) 2010-04-27 2016-08-10 Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων

Country Status (27)

Country Link
US (2) US9505708B2 (enExample)
EP (1) EP2563355B1 (enExample)
JP (3) JP5808392B2 (enExample)
KR (1) KR101851118B1 (enExample)
CN (2) CN105037188B (enExample)
AR (1) AR085171A1 (enExample)
AU (1) AU2011246707B2 (enExample)
BR (1) BR112012027623B1 (enExample)
CA (1) CA2794389C (enExample)
CY (1) CY1117879T1 (enExample)
DK (1) DK2563355T3 (enExample)
EA (1) EA021389B1 (enExample)
ES (1) ES2590128T3 (enExample)
HR (1) HRP20161077T1 (enExample)
HU (1) HUE030504T2 (enExample)
IL (1) IL222532A (enExample)
LT (1) LT2563355T (enExample)
ME (1) ME02509B (enExample)
MX (1) MX342697B (enExample)
NZ (2) NZ602648A (enExample)
PL (1) PL2563355T3 (enExample)
PT (1) PT2563355T (enExample)
RS (1) RS55084B1 (enExample)
SI (1) SI2563355T1 (enExample)
SM (1) SMT201600266B (enExample)
TW (1) TWI492919B (enExample)
WO (1) WO2011134763A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794389C (en) * 2010-04-27 2016-08-23 Newron Pharmaceuticals S.P.A. Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
CN103804341B (zh) * 2012-11-13 2018-04-10 中国人民解放军军事医学科学院毒物药物研究所 酰胺衍生物及其医药用途
CN104761531B (zh) * 2014-01-03 2017-12-01 中国人民解放军军事医学科学院毒物药物研究所 镇痛活性化合物及其医药用途
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
PT1423168E (pt) 2001-09-03 2006-05-31 Newron Pharm Spa Composicao farmaceutica que compreende gabapentina ou um seu analogo e uma x-aminoamida e a sua utilizacao como analgesico
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
EP1596844A2 (en) * 2003-01-30 2005-11-23 Dynogen Pharmaceuticals Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US20070276046A1 (en) 2003-08-25 2007-11-29 Patricia Salvati Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
DK1809271T5 (da) 2004-09-10 2010-12-06 Newron Pharm Spa Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
EP2029524B1 (en) * 2006-06-19 2014-11-26 Newron Pharmaceuticals S.p.A. Process for the production of 2- [4 - ( 3- and 2-fluorobenzyloxy) benzylamino] propan amides
JP5315674B2 (ja) * 2007-11-19 2013-10-16 セントラル硝子株式会社 非水電池用電解液及びこれを用いた非水電池
LT2229351T (lt) * 2007-12-11 2018-01-25 Newron Pharmaceuticals S.P.A. Didelio grynumo laipsnio 2-[4-(3- arba 2-fluorbenziloksi)benzilamino]propanamidų gamybos būdas
NZ586182A (en) 2007-12-19 2012-02-24 Newron Pharm Spa Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
WO2009109334A1 (en) 2008-03-07 2009-09-11 Newron Pharmaceuticals S.P.A. (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
CA2794389C (en) * 2010-04-27 2016-08-23 Newron Pharmaceuticals S.P.A. Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers

Also Published As

Publication number Publication date
KR101851118B1 (ko) 2018-04-23
JP6450420B2 (ja) 2019-01-09
EP2563355B1 (en) 2016-06-08
IL222532A0 (en) 2012-12-31
ES2590128T3 (es) 2016-11-18
US20170029365A1 (en) 2017-02-02
US9856207B2 (en) 2018-01-02
TWI492919B (zh) 2015-07-21
SI2563355T1 (sl) 2016-10-28
AU2011246707B2 (en) 2014-11-20
JP2013528577A (ja) 2013-07-11
BR112012027623A2 (pt) 2016-08-09
HK1213872A1 (zh) 2016-07-15
CA2794389C (en) 2016-08-23
HUE030504T2 (en) 2017-05-29
HRP20161077T1 (hr) 2016-10-21
EA201291116A1 (ru) 2013-04-30
PT2563355T (pt) 2016-09-02
DK2563355T3 (en) 2016-09-12
US9505708B2 (en) 2016-11-29
CN102858330A (zh) 2013-01-02
US20130039983A1 (en) 2013-02-14
MX2012012093A (es) 2012-12-17
EP2563355A1 (en) 2013-03-06
EA021389B1 (ru) 2015-06-30
CN105037188A (zh) 2015-11-11
CA2794389A1 (en) 2011-11-03
NZ700221A (en) 2016-04-29
JP2017197553A (ja) 2017-11-02
JP5808392B2 (ja) 2015-11-10
LT2563355T (lt) 2016-09-26
AR085171A1 (es) 2013-09-18
JP6345154B2 (ja) 2018-06-20
HK1179881A1 (en) 2013-10-11
SMT201600266B (it) 2016-08-31
MX342697B (es) 2016-10-10
JP2015180664A (ja) 2015-10-15
CN105037188B (zh) 2017-06-23
PL2563355T3 (pl) 2016-12-30
ME02509B (me) 2017-02-20
NZ602648A (en) 2014-10-31
KR20130094212A (ko) 2013-08-23
WO2011134763A1 (en) 2011-11-03
IL222532A (en) 2017-09-28
TW201139344A (en) 2011-11-16
BR112012027623B1 (pt) 2021-07-06
CN102858330B (zh) 2015-07-22
RS55084B1 (sr) 2016-12-30

Similar Documents

Publication Publication Date Title
CY1117879T1 (el) Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων
EA202090917A1 (ru) Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение
EP2735616A4 (en) METHOD OF PREPARING PEPTIDES FROM CASEIN BY MILKIC ACID FERTILIZATION
WO2011123668A3 (en) Stereoselective synthesis of phosphorus containing actives
BRPI0915692B8 (pt) compostos derivados de 1,2,5-oxadiazóis, sua forma sólida, sua composição, bem como seus usos
EP2327691A4 (en) METHOD FOR PRODUCING A SULFURIC ACID GROUP-CONTAINING ETHER COMPOUND
EP2471943A4 (en) PROCESS FOR THE PREPARATION OF L-AMINO ACID
BR112014014060A2 (pt) processo para a preparação de travoprosta
EP2215050A4 (en) PROCESS FOR THE PREPARATION OF 2-HYDROXY-5-PHENYL ALKYLAMINOBENZOESÄUREDERIVATEN AND THEIR SALTS
EP2447243A4 (en) PROCESS FOR THE PREPARATION OF KETOMALONIC COMPOUNDS OR HYDRATES THEREOF
EP2690086A4 (en) NEW CARBONIC ACID SUBSTITUTE COMPOSITION, MANUFACTURING METHOD AND SUBSTANCE PREPARATION
EP3438084A4 (en) PROCESS FOR THE PRODUCTION OF HYDROXYCIC ACID
EP2006274A4 (en) Method for producing 3,3,3-trifluoropropionic acid chloride
EA201201666A1 (ru) Промежуточные соединения агомелатина и способ их получения
EP3381887A4 (en) PROCESS FOR PREPARING ACETIC ACID
ITMI20120311A1 (it) Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato
FR2926080B1 (fr) Procede de synthese de derives d'acide hydroxy-bisphosphonique
ES2540211T3 (es) Proceso para preparar una amida de un ácido carboxílico pirazólico
EP4172108C0 (en) Method for producing active carbon
EP4332111A4 (en) METHOD FOR PRODUCING AN OLIGONUCLEIC ACID COMPOUND
EP3599231A4 (en) Acetic acid production method
ES2381813T3 (es) Procedimiento para la preparación de ésteres del ácido 2,3,4,9-tetrahidro-1H-beta-carbolin-3-carboxílico
EA200801348A1 (ru) Способ получения промежуточных соединений хлорамфеникола или его аналогов
EP2460882A4 (en) PROCESS FOR THE PREPARATION OF MILKY ACID
BR112014029361A2 (pt) método de produção de ácido tereftálico e seus derivados